CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the phase 1 portion of its ongoing phase 1/2 study of tazemetostat will be presented during the European Cancer Congress 2015, hosted by the European Society of Medical Oncology (ESMO), to be held in Vienna, Austria, September 25-28, 2015. Tazemetostat is a first-in-class EZH2 inhibitor that Epizyme is currently studying in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (NHL) and advanced solid tumors, including INI1-deficient tumors.
Help employers find you! Check out all the jobs and post your resume.
